Review paper
Long-term safety of ketamine and esketamine in treatment of depression
Abstract
Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019. Here we review what is known about the long-term safety of both racemic ketamine and esketamine as therapies for psychiatric disorders.In this article, we conducted a safety review of ketamine and esketamine. In looking at ketamine and esketamine long-term...
Paper Details
Title
Long-term safety of ketamine and esketamine in treatment of depression
Published Date
Apr 13, 2022
Volume
21
Issue
6
Pages
777 - 787